Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial
- Ann. Surg., Volume 268, Issue 2, 1 August 2018, Pages 215-222 | 10.1097/SLA.0000000000002705